TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34306265
Drug: LABA +
Normalized name: Labafenogene marselecobac
DrugBank: Labafenogene marselecobac (DB17618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LABA + inhaled corticosteroid (formoterol/budesonide)
Study: 34306265
Drug: LAMA +
Normalized name: Lama palagi oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAMA + inhaled corticosteroid (tiotropium/budesonide)
Study: 35032204
Drug: Gastrotuss® (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrotuss® (20 ml, three daily doses)
Study: 35032204
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg, once daily)
Study: 34455728
Drug: Aromatherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatherapy with rose essential oil (REO), 3 drops by inhalation, three times a day for 3 days
Study: 34455728
Drug: Placebo, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 3 drops by inhalation, three times a day for 3 days
Study: 32927487
Drug: Calcitriol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (0.25 μg pills, 2 pills daily for 4 weeks)
Study: 32482534
Drug: Adjuvant mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant mFOLFOX6 (oxaliplatin 85 mg/m², leucovorin 400 mg/m², and 5‐FU bolus 400 mg/m² then 5FU Continuous infusion 2.4 g/m²) every two weeks for 12 cycles
Study: 33864109
Drug: Olfactory training
Normalized name: BOS TAURUS OLFACTORY BULB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olfactory training (OT) performed twice a day
Study: 32969384
Drug: Infusion therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion therapy (furosemide infusion at 2mg/hour and albumin at 2g/hour for three days)
Study: 32969384
Drug: Bolus therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus therapy (intravenous albumin and furosemide as boluses)
Study: 34424102
Drug: Contingency management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency management techniques (consequent-based condition - CC)
Study: 34474038
Drug: PTG-100 (150,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTG-100 (150, 300, or 900 mg)
Study: 33749997
Drug: Diclofenac-Hyaluronate Conjugate
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diclofenac-Hyaluronate Conjugate (DF-HA) 30 mg, administered via intraarticular injection once every 4 weeks for 20 weeks (total of 6 injections)
Study: 33749997
Drug: Placebo (citric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (citric acid-sodium citrate buffered solution), administered via intraarticular injection once every 4 weeks for 20 weeks (total of 6 injections)
Study: 32593960
Drug: Conventional overground
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional overground therapy (CT)
Study: 37178149
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (control group)
Study: 32554183
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) administration
Study: 34292451
Drug: Pazopanib (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib (median dose 150 mg daily for a median of 22 months)
Study: 34047133
Drug: Child Compound
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child Compound Endothelium Corneum (CCEC)
Study: 33558250
Drug: Paediatric drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paediatric drug RCTs published in 2017-2018
Study: 32784188
Drug: Fatigue in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fatigue in Teenagers on the InterNET, a web-based modular CFS/ME-specific cognitive behavioral therapy program supported by individualized clinical psychologist electronic consultations.
Study: 34327798
Drug: Oral simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral simvastatin
Study: 37804189
Drug: Lipid-lowering treatment
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering treatment
Study: 33113295
Drug: LY-CoV555 2800
Normalized name: LYS
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LY-CoV555 2800 mg
Study: 33113295
Drug: LY-CoV555 700
Normalized name: LYS
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LY-CoV555 700 mg
Study: 33113295
Drug: LY-CoV555 7000
Normalized name: LYS
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LY-CoV555 7000 mg
Study: 33113295
Drug: LY-CoV555 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY-CoV555 (all doses combined)
Study: 36394295
Drug: Interactive web-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive web-based self-management system for hypertension (daily measurement of BP and pulse, reports of well-being, symptoms, lifestyle, medication intake, side effects, reminders, motivational messages) for 8 weeks
Study: 33549381
Drug: PRICE therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRICE therapy (protection, rest, ice (cryotherapy at 3°C), compression (35 mm Hg), elevation)
Study: 33657679
Drug: Melatonin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (2 mg per day at night)
Study: 36921619
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with Chinese herbal medicine (CHM)
Study: 33780573
Drug: CC-486 as
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-486 as maintenance therapy
Study: 33780573
Drug: Venetoclax and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax and azacitidine combination
Study: 36728194
Drug: Any therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any therapy
Study: 33622382
Drug: Probiotics (840
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (840 mg bid) plus dietary fiber (30 g bid)
Study: 33622382
Drug: Probiotics (840
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (840 mg bid) plus placebo
Study: 33622382
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus dietary fiber (30 g bid)
Study: 35338764
Drug: I gel
Normalized name: Omni Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: I gel
Study: 35834762
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy followed by autologous stem-cell transplantation (ASCT)
Study: 35439775
Drug: Blepharoexfoliation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blepharoexfoliation with tea tree oil 2% shampoo followed by eyelid scrubs with tea tree oil 2% shampoo twice a day for 8 weeks
Study: 35439775
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with sham blepharoexfoliation and eyelid scrubs with tea tree oil 2% shampoo twice a day for 8 weeks
Study: 33440080
Drug: Fotagliptin (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fotagliptin (24 mg, once-daily for 14 days)
Study: 33440080
Drug: Placebo (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (once-daily for 14 days)
Study: 35099523
Drug: Multicomponent vaccine
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent vaccine campaign
Study: 38152404
Drug: Antifungal treatment
Normalized name: TOLNAFTATE 10 mg in 1 mL TOPICAL LIQUID [Liquid Antifungal Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifungal treatment
Study: 35575751
Drug: Closed-loop therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop therapy (MiniMed 670G)
Study: 34410322
Drug: High-Intensity Interval
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Interval Training (HIIT) - 12 weeks, thrice-weekly, supervised aerobic sessions at 85% to 95% of peak oxygen consumption (V̇o2)
Study: 32271150
Drug: eHealth intervention
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: eHealth intervention for weekly monitoring of side effects using PRO-CTCAE questions
Study: 32271150
Drug: eHealth intervention
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: eHealth intervention for weekly monitoring of side effects
Study: 33238154
Drug: Domperidone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (10 mg)
Study: 34646885
Drug: Immediate Implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Implant Placement (IIP)
Study: 34646885
Drug: Delayed Implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed Implant Placement (DIP)
Study: 35229767
Drug: Conventional root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional root canal therapy along with LLLT
Study: 35229767
Drug: Conventional root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional root canal therapy only
Study: 32751340
Drug: Periodontal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal treatment in conjunction with ozone gas therapy
Study: 32751340
Drug: Standard periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard periodontal treatment
Study: 36334223
Drug: Celery seed
Normalized name: CELERY SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celery seed extract (1.34 g per day)
Study: 33161045
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity interval training (HIIT) - 4x4‐minute sessions, 3 times weekly for 4 weeks, followed by 3 home-based sessions weekly for 48 weeks
Study: 33161045
Drug: Moderate intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate intensity continuous training (MICT) - 40 minutes, usual care, 3 times weekly for 4 weeks, followed by 3 home-based sessions weekly for 48 weeks
Study: 37188468
Drug: Caffeine 3
Normalized name: caffeine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 3 mg/kg
Study: 33857414
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg intravenously every 3 weeks for 1 year)
Study: 34108716
Drug: ChAdOx1 nCoV-19
Normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 nCoV-19 (Oxford–AstraZeneca) vaccine
Study: 34108716
Drug: BNT162b2 (Pfizer–BioNTech)
Normalized name: Pfizer-BioNTech COVID-19 Vaccine
DrugBank: Tozinameran (DB15696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 (Pfizer–BioNTech) vaccine
Study: 35261318
Drug: siponimod (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: siponimod (2 mg/day)
Study: 32114709
Drug: Subretinal injection
Normalized name: LUXTURNA Suspension for Subretinal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subretinal injection of conbercept (0.5 mg/0.05 ml)
Study: 32114709
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of conbercept (0.5 mg/0.05 ml)
Study: 38293149
Drug: Small-quantity lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-quantity lipid-based nutrient supplements (SQ-LNS)
Study: 33471086
Drug: HTX-011 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX-011 (up to 60 mg bupivacaine/1.8 mg meloxicam) as the foundation of multimodal analgesia (MMA) regimen with ibuprofen (600 mg) and acetaminophen (1 g) every 3 hours for 72 hours.
Study: 33471086
Drug: HTX-011 with
Normalized name: Human papillomavirus virus-like particles conjugated with ir700 dye au-011
DrugBank: Belzupacap Sarotalocan (DB17317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX-011 with scheduled ibuprofen and acetaminophen.
Study: 35710091
Drug: Inspiratory Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory Muscle Training (IMT) plus Compression Therapy (CT)
Study: 35710091
Drug: Calf Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calf Muscle Exercise Training (CMET) plus Compression Therapy (CT)
Study: 35710091
Drug: Compression Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression Therapy (CT) alone
Study: 34258509
Drug: Odanacatib (anti‐cathepsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib (anti‐cathepsin K monoclonal antibody)
Study: 34258509
Drug: Romosozumab (anti‐sclerostin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romosozumab (anti‐sclerostin monoclonal antibody)
Study: 35549904
Drug: Midazolam/pethidine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam/pethidine combination
Study: 33793143
Drug: Glycine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycine (3 g twice a day for 4 weeks)
Study: 33793143
Drug: Glucose (placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (placebo, 3 g twice a day for 4 weeks)
Study: 32115159
Drug: Average monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Average monthly income
Study: 35655483
Drug: Routine nursing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine nursing of gynecological malignant tumor chemotherapy
Study: 32862577
Drug: Reduced glutathione
Normalized name: Reduced glutathione
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced glutathione (GSH) treatment
Study: 34371524
Drug: daridorexant 50
Normalized name: daridorexant 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: daridorexant 50 mg single dose
Study: 34371524
Drug: famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 40 mg single dose + daridorexant 50 mg single dose
Study: 34371524
Drug: efavirenz 600
Normalized name: efavirenz 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: efavirenz 600 mg once a day for 10 days
Study: 34371524
Drug: daridorexant 50
Normalized name: daridorexant 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: daridorexant 50 mg single dose + efavirenz 600 mg once a day for 2 days
Study: 34964736
Drug: Oral mirtazapine
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral mirtazapine (Control)
Study: 35622185
Drug: MitraClip plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MitraClip plus optimal medical therapy (OMT)
Study: 33054556
Drug: Tolcapone (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolcapone (a catechol-O-methyltransferase inhibitor)
Study: 35543936
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical symptomatic treatment + NMES and rehabilitation training (Control group)
Study: 32335860
Drug: Tongguan Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongguan Capsules (4.5 g/d) for 3 months
Study: 32335860
Drug: Standard anti-platelet,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anti-platelet, anti-coagulation and lipid-decreasing treatments
Study: 35792926
Drug: 10-week, multimodal,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-week, multimodal, bi-weekly exercise intervention (EG)
Study: 32418174
Drug: Nux Vomica
Normalized name: Nux vomica
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nux Vomica Capsule (NVC, 0.4 g, thrice daily) for 30 days
Study: 33634794
Drug: Low Glycemic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Glycemic Index Treatment (LGIT)
Study: 32467089
Drug: Two times
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two times a day proton pump inhibitor (PPI)
Study: 39515580
Drug: Magnetic Seizure
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetic Seizure Therapy (MST)
Study: 33125448
Drug: Electroconvulsive Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive Therapy (ECT) - Bitemporal (BT)
Study: 33125448
Drug: Electroconvulsive Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive Therapy (ECT) - Right Unilateral (RUL)
Study: 38638400
Drug: Ranibizumab 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.2 mg
Study: 34942508
Drug: Cultural dexterity
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cultural dexterity curriculum (not specified dosage or duration)
Study: 35367279
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) 800 mg
Study: 33864831
Drug: Daily SBP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily SBP
Study: 33785226
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no pharmacologic treatment)
Study: 32077207
Drug: Temelimab 6
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temelimab 6 mg/kg
Study: 35488452
Drug: Cognitive‐Behavioral Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐Behavioral Therapy
Study: 34003568
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy regimen (hydrocortisone 50 mg/6-h IV for 7 days, vitamin C 1.5 g/6-h IV for 4 days, thiamine 200 mg/12-h IV for 4 days)
Study: 34003568
Drug: Hydrocortisone monotherapy
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone monotherapy (hydrocortisone 50 mg/6-h IV for 7 days)
Study: 34003568
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy regimen
Study: 33534617
Drug: Sitafloxacin 100
Normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sitafloxacin 100 mg qd
Study: 33534617
Drug: Sitafloxacin 100
Normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sitafloxacin 100 mg bid
Study: 33534617
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg qd
Study: 34391281
Drug: Intramuscular stimulation
Normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular stimulation (IMS) to the pronator teres muscle, depth of 45-50 mm, 7 treatments over 7 weeks
Study: 34391281
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received acupuncture needle at Li11, depth of 4-5 mm, 7 treatments over 7 weeks
Study: 38271308
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of diuretics
Study: 35318791
Drug: Mixed preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed preparation containing piperine, capsaicin, and curcumin, applied topically twice daily for 3 months.
Study: 35318791
Drug: 5% minoxidil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% minoxidil, applied topically once daily for 3 months.
Study: 38688118
Drug: Subcutaneous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous ketamine
Study: 32542733
Drug: Tigilanol tiglate
Normalized name: Tigilanol Tiglate
DrugBank: Tigilanol tiglate (DB18800)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigilanol tiglate (TT) 1 mg/mL injected intratumorally
Study: 32762030
Drug: Silybum marianum
Normalized name: Silybum marianum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silybum marianum extract (400 mg/d)
Study: 33045501
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (50 mg orally every 8 hours during labor)
Study: 35752091
Drug: 36 mg/ml
Normalized name: iodine 36 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 mg/ml e‐cigarette
Study: 35752091
Drug: 8 mg/ml
Normalized name: valine 8 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/ml e‐cigarette
Study: 35752091
Drug: 0 mg/ml
Normalized name: urea 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/ml e‐cigarette
Study: 36228453
Drug: ISP group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISP group received bilateral ultrasound guided ISP block at the level of C5 using 20 ml bupivacaine 0.25% on each side
Study: 34910161
Drug: HIIT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIIT with FOS-enriched inulin (12 g·d‐1)
Study: 33784438
Drug: Antenatal nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal nutritional supplements
Study: 34371872
Drug: Peptide formula
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide formula (PF) 1.5 kcal/mL
Study: 34403141
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of intravenous squalene twice a day and standard treatment for 6 days
Study: 35488787
Drug: Esketamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine (0.3 mg/kg) combined with propofol
Study: 35488787
Drug: Dezocine (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dezocine (0.05 mg/kg) combined with propofol
Study: 32621262
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBMT) associated with Preventive Oral Care Program (POCP)
Study: 33534895
Drug: Nolasiban 900
Normalized name: Nolasiban
DrugBank: Nolasiban (DB16259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nolasiban 900 mg
Study: 33739022
Drug: Nolasiban 1800
Normalized name: Nolasiban
DrugBank: Nolasiban (DB16259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nolasiban 1800 mg
Study: 33739022
Drug: Sex hormones
Normalized name: GENITO URINARY SYSTEM AND SEX HORMONES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex hormones (independent assessment)
Study: 32020824
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (0.04% tretinoin microspheres + 1% clindamycin)
Study: 32020824
Drug: Monotherapy (0.025%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (0.025% tretinoin)
Study: 32020824
Drug: Monotherapy (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (1% clindamycin)
Study: 32082606
Drug: Oral probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral probiotics